Concourse Financial Group Securities, Inc. Nuvation Bio Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

19 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$1.66 - $2.53 $0 - $0
Q1 2025 May 14, 2025	BUY	$1.76 - $3.25 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$2.01 - $3.01 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$2.3 - $3.83 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.58 - $3.69 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.46 - $3.97 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.96 - $1.53 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.26 - $2.1 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.26 - $2.1 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.56 - $1.84 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.68 - $2.5 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.29 - $4.04 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.24 - $5.85 $0 - $0
Q1 2022 May 09, 2022	BUY	$4.6 - $8.83 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$7.75 - $10.05 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$7.78 - $10.0 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$9.22 - $14.48 $0 - $0
Q1 2021 May 13, 2021	BUY	$9.0 - $14.57 $0 - $0

Others Institutions Holding NUVB

# of Institutions

201

Shares Held

171M

Call Options Held

2.31M

Put Options Held

221K

Decheng Capital LLC Menlo Park, CA

26M
Shares

$129 Million
12.78% of portfolio
Black Rock Inc. New York, NY

16.2M
Shares

$80.9 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

15.5M
Shares

$77 Million
0.0% of portfolio
Omega Fund Management, LLC Boston, MA

11M
Shares

$55 Million
46.36% of portfolio
Laurion Capital Management LP New York, NY

10.2M
Shares

$51 Million
0.37% of portfolio

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $1.08B
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account